Considerations for widespread implementation of blood-based biomarkers of Alzheimer's disease.

Autor: Mielke MM; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA., Anderson M; Atrium Health, Charlotte, North Carolina, USA., Ashford JW; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, California, USA.; War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, California, USA., Jeromin A; ALZpath, Carlsbad, California, USA., Lin PJ; Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA., Rosen A; Palo Alto Veterans Affairs Medical Center, Palo Alto, California, USA.; Stanford University School of Medicine, Stanford, California, USA., Tyrone J; Patient Advocate, California, USA., VandeVrede L; Memory and Aging Center, Department of Neurology, University of California, San Francisco, California, USA., Willis D; Department of Family Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA., Hansson O; Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden.; Memory Clinic, Skåne University Hospital, Malmö, Sweden., Khachaturian AS; The Campaign to Prevent Alzheimer's Disease, Rockville, Maryland, USA., Schindler SE; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, Missouri, USA., Weiss J; US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Workforce, Rockville, Maryland, USA., Batrla R; Eisai Inc., Nutley, New Jersey, USA., Bozeat S; F. Hoffman-La Roche AG, Basel, Switzerland., Dwyer JR; Global Alzheimer's Platform Foundation, Washington, District of Columbia, USA., Holzapfel D; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.; Davos Alzheimer's Collaborative, Philadelphia, Pennsylvania, USA., Jones DR; Eisai Inc., Nutley, New Jersey, USA., Murray JF; Davos Alzheimer's Collaborative, Philadelphia, Pennsylvania, USA., Partrick KA; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA., Scholler E; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.; Davos Alzheimer's Collaborative, Philadelphia, Pennsylvania, USA., Vradenburg G; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, Pennsylvania, USA.; Davos Alzheimer's Collaborative, Philadelphia, Pennsylvania, USA., Young D; Guidehouse, McLean, Virginia, USA., Braunstein JB; C2N Diagnostics, St. Louis, Missouri, USA., Burnham SC; Eli Lilly & Co., Indianapolis, Indiana, USA., de Oliveira FF; Federal University of São Paulo, São Paulo, Brazil., Hu YH; Eisai Inc., Nutley, New Jersey, USA., Mattke S; The USC Brain Health Observatory, University of Southern California, Los Angeles, California, USA., Merali Z; Brain and Mind Institute, Aga Khan University, Nairobi, Kenya., Monane M; C2N Diagnostics, St. Louis, Missouri, USA., Sabbagh MN; Barrow Neurological Institute, Phoenix, Arizona, USA., Shobin E; Biogen, Cambridge, Massachusetts, USA., Weiner MW; Departments of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology, University of California, San Francisco, California, USA., Udeh-Momoh CT; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, North Carolina, USA.; Brain and Mind Institute, Aga Khan University, Nairobi, Kenya.

Publikováno v: Alzheimer's & dementia : the journal of the Alzheimer's Association [Alzheimers Dement] 2024 Nov; Vol. 20 (11), pp. 8209-8215. Date of Electronic Publication: 2024 Oct 06.

Acceptable performance of blood biomarker tests of amyloid pathology - recommendations from the Global CEO Initiative on Alzheimer's Disease.

Autor: Schindler SE; Department of Neurology, Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St Louis, MO, USA. schindler.s.e@wustl.edu., Galasko D; Department of Neurosciences, University of California, San Diego, La Jolla, CA, USA., Pereira AC; Department of Neurology, Icahn School of Medicine, Mount Sinai, New York, NY, USA., Rabinovici GD; Department of Neurology, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.; Department of Radiology and Biomedical Imaging, Weill Institute for Neurosciences, University of California, San Francisco, CA, USA., Salloway S; Department of Neurology, Alpert Medical School, Brown University, Providence, RI, USA., Suárez-Calvet M; Barcelonaβeta Brain Research Center, Pasqual Maragall Foundation, Barcelona, Spain., Khachaturian AS; The Campaign to Prevent Alzheimer's Disease, Rockville, MD, USA., Mielke MM; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Udeh-Momoh C; Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, NC, USA., Weiss J; US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Workforce, Rockville, MD, USA., Batrla R; Eisai Inc., Nutley, NJ, USA., Bozeat S; F. Hoffman-La Roche AG, Basel, Switzerland., Dwyer JR; Global Alzheimer's Platform Foundation, Washington, DC, USA., Holzapfel D; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, PA, USA., Jones DR; Eisai Inc., Nutley, NJ, USA., Murray JF; Davos Alzheimer's Collaborative, Philadelphia, PA, USA., Partrick KA; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, PA, USA., Scholler E; The Global CEO Initiative on Alzheimer's Disease, Philadelphia, PA, USA., Vradenburg G; Davos Alzheimer's Collaborative, Philadelphia, PA, USA.; UsAgainstAlzheimer's, Washington, DC, USA., Young D; Guidehouse, McLean, VA, USA., Algeciras-Schimnich A; Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Aubrecht J; Prothena Biosciences Inc., Brisbane, CA, USA., Braunstein JB; C2N Diagnostics, St Louis, MO, USA., Hendrix J; Eli Lilly and Company, Indianapolis, IN, USA., Hu YH; Eisai Inc., Nutley, NJ, USA., Mattke S; The USC Brain Health Observatory, University of Southern California, Los Angeles, CA, USA., Monane M; C2N Diagnostics, St Louis, MO, USA., Reilly D; Guidehouse, McLean, VA, USA., Somers E; Eisai Inc., Nutley, NJ, USA., Teunissen CE; Neurochemistry Laboratory, Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam University Medical Centers, Vrije Universitiet, Amsterdam, The Netherlands., Shobin E; Biogen, Cambridge, MA, USA., Vanderstichele H; Biomarkable BV, Gent, Belgium., Weiner MW; Department of Radiology and Biomedical Imaging, University of California, San Francisco, CA, USA.; Department of Medicine, University of California, San Francisco, CA, USA.; Department of Psychiatry, University of California, San Francisco, CA, USA.; Department of Neurology, University of California, San Francisco, CA, USA., Wilson D; Quanterix Corporation, Billerica, MA, USA., Hansson O; Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden. oskar.hansson@med.lu.se.; Memory Clinic, Skåne University Hospital, Malmö, Sweden. oskar.hansson@med.lu.se.

Publikováno v: Nature reviews. Neurology [Nat Rev Neurol] 2024 Jul; Vol. 20 (7), pp. 426-439. Date of Electronic Publication: 2024 Jun 12.

Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review.

Autor: Garcia MJ; F. Hoffmann-La Roche, Ltd., Basel, Switzerland., Leadley R; Mtech Access Ltd, IT Centre, Innovation Way, Heslington, York, UK., Ross J; Mtech Access Ltd, IT Centre, Innovation Way, Heslington, York, UK., Bozeat S; F. Hoffmann-La Roche, Ltd., Basel, Switzerland., Redhead G; Mtech Access Ltd, IT Centre, Innovation Way, Heslington, York, UK., Hansson O; Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden.; Memory Clinic, Skåne University Hospital, Lund, Sweden., Iwatsubo T; The University of Tokyo, Tokyo, Japan., Villain N; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France.; Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau -ICM, Paris, France., Cummings J; Chambers-Grundy Center for TransformativeNeuroscience, Department of Brain Health, School of IntegratedHealth Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.

Publikováno v: Journal of Alzheimer's disease reports [J Alzheimers Dis Rep] 2024 Feb 16; Vol. 8 (1), pp. 203-240. Date of Electronic Publication: 2024 Feb 16 (Print Publication: 2024).

Biomarkers in Alzheimer's disease: role in early and differential diagnosis and recognition of atypical variants.

Autor: Dubois B; Assistance Publique-Hôpitaux de Paris (AP-HP), Memory and Alzheimer's Disease Institute, Sorbonne University, Paris, France.; Brain Institute, Sorbonne University, Paris, France., von Arnim CAF; Department of Geriatrics, University Medical Center Göttingen, Göttingen, Germany. christine.arnim@med.uni-goettingen.de., Burnie N; General Practice, South West London CCG, London, UK.; London Dementia Clinical Network, London, UK., Bozeat S; F. Hoffmann-La Roche AG, Basel, Switzerland., Cummings J; Chambers-Grundy Center for Transformative Neuroscience, Pam Quirk Brain Health and Biomarker Laboratory, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA.

Publikováno v: Alzheimer's research & therapy [Alzheimers Res Ther] 2023 Oct 13; Vol. 15 (1), pp. 175. Date of Electronic Publication: 2023 Oct 13.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.